Research Paper Volume 11, Issue 11 pp 3811—3823
Long non-coding RNA AGAP2-AS1 exerts oncogenic properties in glioblastoma by epigenetically silencing TFPI2 through EZH2 and LSD1
Figure 1. AGAP2-AS1 expression is overexpressed in GBM and correlated with poor prognosis of GBM patients. (A) AGAP2-AS1 expression in GBM tissues (n=163) and normal tissues (n=207) in from GEPIA database (http://gepia.cancer-pku.cn/detail.php?gene=&clicktag=boxplot). (B) qRT-PCR analysis of AGAP2-AS1 expression in tumor tissues and matched surrounding tissues from 58 patients with GBM. (C) qRT-PCR analysis of AGAP2-AS1 enrichment in five GBM cells (A172, U87/MG, U251/MG, LN229, SHG44) and normal human astrocytes (NHA). (D) Kaplan-Meier analysis of overall survival in GBM patients according to AGAP2-AS1 expression levels. *P < 0.05, **P < 0.01, ***P < 0.001.